Twist Bioscience (TWST): Initiation of Coverage (2023-2026)
Key Points
- Sustained Revenue Growth: Revenue grew from $245.1M in FY2023 to $376.6M in FY2025 (+53.6% over two years), with Q3 2026 revenue at $118.4M (+23% YoY).
- Margin Expansion: Gross margin improved from 36.6% in FY2023 to 50.7% in FY2025, reaching 52.8% in Q3 2026.
- Path to Profitability: Net losses narrowed from -$204.6M in FY2023 to -$77.7M in FY2025; company expects adjusted EBITDA breakeven in Q4 FY26.
- Product and Segment Diversification: NGS tools and synthetic genes are core growth drivers; AI-enabled drug discovery now a major engine, with DSPS segment up 39% YoY in Q3 2026.
- Customer Base Expansion: Customers served grew from 3,450 in FY2023 to >3,800 in FY2025; 99% of revenue from repeat customers.
- Strategic Moves: Spun out DNA data storage business (Atlas Data Storage) in FY2025, focusing on core synthetic biology, NGS, and biopharma.
- Solid Liquidity: Ended FY2025 with $183.0M in cash and $49.4M in short-term investments; Q3 2026 cash, equivalents & ST investments at $166.8M.
Business Overview
Twist Bioscience is a synthetic biology company leveraging a proprietary semiconductor-based DNA synthesis platform. The company serves therapeutics, diagnostics, industrial, academic, and government markets, with a focus on high-throughput, cost-effective DNA and protein production. Its business is structured around DNA Synthesis & Protein Solutions (DSPS) and NGS Applications, with a growing emphasis on AI-enabled drug discovery.
Financial Snapshot: Fiscal Years Ended September 30
| Fiscal Year | Revenue ($M) | YoY Growth | Gross Margin (%) | Operating Loss ($M) | Net Loss ($M) | Cash & Equiv. ($M) | Short-term Investments ($M) | Genes Shipped (000s) | Customers Served | Revenue from Repeat Customers (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 376.6 | +20.3% | 50.7 | -136.3 | -77.7 | 183.0 | 49.4 | 938 | >3,800 | 99 |
| 2024 | 313.0 | +27.7% | 42.6 | -220.8 | -208.7 | 226.3 | 50.1 | 772 | >3,550 | 98 |
| 2023 | 245.1 | +20% | 36.6 | -217.2 | -204.6 | 289.3 | - | - | - | - |
Financial Snapshot: Quarterly Trend (Q1-Q3 FY26)
| Quarter | Revenue ($M) | Gross Margin (%) | Adj. EBITDA ($M) | Cash, Equiv. & ST Inv. ($M) |
|---|---|---|---|---|
| Q3 2026 | 118.4 | 52.8 | -11.3 | 166.8 |
| Q2 2026 | 110.7 | 51.6 | -13.3 | 171.7 |
| Q1 2026 | 103.7 | 52.0 | -13.4 | 197.9 |
Segment Revenue Breakdown: Q3 2026
| Segment | Revenue ($M) | YoY Growth |
|---|---|---|
| DNA Synthesis & Protein Solutions (DSPS) | 56.6 | +39% |
| NGS Applications | 61.8 | +12% |
| Total Company | 118.4 | +23% |
Industry Revenue Breakdown: Q3 2026
| Industry Segment | Revenue ($M) | YoY Growth | Notes |
|---|---|---|---|
| Therapeutics | 40.4 | +49% | Driven by AI-enabled drug discovery |
| Diagnostics | 43.8 | +15% | Strong growth in top accounts |
| Industry & Applied | 5.7 | - | - |
| Academic & Government | 15.5 | +32% | Sequential and YoY growth, US strength |
| Global Supply Partners | 12.9 | - | Stable recurring base |
Key Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Sustained double-digit revenue growth (14 consecutive quarters) | Company remains unprofitable; net loss of -$77.7M in FY2025 |
| Gross margin expansion to 50.7% in FY2025, >52% in Q3 2026 | High operating expenses, especially in SG&A ($247.0M in FY2025, +13% YoY) |
| AI-enabled drug discovery is a durable, repeatable growth engine | R&D spending remains high, though declining ($80.3M in FY2025) |
| Strong customer retention (99% revenue from repeat customers in FY2025) | Academic/government segment faces funding pressures |
| Platform scalability and automation drive operating leverage | Competition from established players (e.g., GenScript) and new entrants |
| Broadening product portfolio (complex genes, proprietary enzymes, MRD panels) | Some pricing pressure in academic and smaller gene segments |
| Solid liquidity position ($232.4M in cash & investments at FY2025 end) | Accumulated deficit of $1,319.6M as of FY2025 |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Ramp-up of AI-enabled drug discovery orders (triple-digit growth) | Slowdown in AI/biopharma R&D spending |
| New product launches (complex genes, proprietary enzymes, MRD) | Delays in customer commercialization or validation cycles |
| Expansion of NGS applications in diagnostics and MRD | Increased competition or price compression |
| Achieving and sustaining adjusted EBITDA breakeven | Regulatory or reimbursement headwinds in diagnostics |
| Further automation and capacity expansion | Execution risk in scaling new offerings |
| Entry into new modalities (bispecifics, nucleic acid therapeutics) | Macro funding constraints in academic/government segments |
| Realization of value from Atlas Data Storage spinout | Litigation outcomes (e.g., ongoing securities class action) |
Top Questions to Ask Before Investing
- AI Demand Durability: How sustainable is the current wave of AI-enabled drug discovery demand? What evidence supports ongoing triple-digit order growth into FY27 and beyond?
- Profitability Path: Beyond adjusted EBITDA breakeven, what is the timeline and pathway to full GAAP profitability and positive free cash flow?
- Competitive Landscape: How does Twist’s platform compare to competitors like GenScript, especially in protein/data characterization and large-scale pooled DNA synthesis?
- Customer Concentration: What is the risk associated with top customer concentration, particularly in NGS and AI-driven segments?
- Margin Expansion: What are the key levers to drive gross margin from the current 52-53% to the >60% target? Are there risks to this trajectory?
- Product Adoption: How quickly are new products (complex genes, proprietary enzymes, MRD panels) being adopted, and what is their incremental contribution to growth?
- Capital Allocation: How will Twist balance investment in growth (R&D, automation, commercial) with the need for operating leverage and cash preservation?
- Macro Sensitivity: How exposed is Twist to macroeconomic or sector-specific funding cycles, especially in academic/government and early-stage biotech?
- Regulatory/Reimbursement Risk: What are the key regulatory or reimbursement hurdles for diagnostic and MRD applications, and how is Twist positioned to navigate them?
- Long-Term Market Opportunity: What is the company’s strategy to expand its addressable market beyond the current $13B projection by 2030?
Investment Story (2023-2026)
Twist Bioscience has executed a multi-year transformation from a high-growth, high-burn synthetic biology innovator to a more operationally efficient, margin-expanding platform company. Over the last three years, the company has:
- Accelerated Revenue Growth: Revenue increased from $245.1M in FY2023 to $376.6M in FY2025, with quarterly revenue reaching $118.4M in Q3 2026 (+23% YoY). This growth has been driven by strong adoption of NGS tools, synthetic genes, and, more recently, AI-enabled drug discovery.
- Expanded Margins: Gross margin improved from 36.6% in FY2023 to 50.7% in FY2025, and further to 52.8% in Q3 2026, reflecting operational efficiencies, product mix shift, and scale.
- Narrowed Losses: Net losses have narrowed significantly, from -$204.6M in FY2023 to -$77.7M in FY2025, with the company targeting adjusted EBITDA breakeven in Q4 FY26.
- Broadened Product Portfolio: The launch of Express Genes, proprietary enzymes, and MRD panels has diversified the revenue base and supported margin expansion.
- Strategic Refocus: The spinout of the DNA data storage business (Atlas Data Storage) in FY2025 sharpened the company’s focus on core synthetic biology, NGS, and biopharma markets, while providing potential future upside via equity, milestones, and royalties.
- Strengthened Customer Base: The customer base has grown to over 3,800, with 99% of revenue from repeat customers, and significant penetration in healthcare, diagnostics, and AI-driven therapeutics.
- Solidified Liquidity: Despite ongoing losses, Twist maintains a strong liquidity position, ending FY2025 with $232.4M in cash and investments, and $166.8M as of Q3 2026.
The next phase of the story centers on sustaining high growth in AI-enabled drug discovery, achieving and maintaining profitability, and defending competitive advantages in a rapidly evolving synthetic biology landscape.
